Boehringer Ingelheim launches ProZinc, a new cat insulin product

ProZinc is a new cat insulin product that is optimised for twice-daily dosing and comes in a 60-day owner-friendly package, was launched by Boehringer Ingelheim at BSAVA Congress.

On the Boehringer Ingelheim stand the team were serving chilled drinks and discussing the issue with visitors – one in 250 cats is diabetic.

Dan Hughes said: “This is our favourite spot and handing out drinks enables us to get the message out about our new product, the whole stand is dedicated to it.”